Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2000-10-18
2010-11-02
Ford, Vanessa L. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C435S174000, C436S519000, C530S324000, C530S350000, C536S023100
Reexamination Certificate
active
07824695
ABSTRACT:
This invention provides bioactive conjugates. The bioactive conjugates include: (1) a cell recognition moiety that binds to α2macroglobulin receptor α2-MR and (2) a bioactive moiety which: (a) has a biological activity, (b) does not function solely as an immunogen to invoke an immune response and (c) does not have ADP ribosylating activity. The bioactive conjugates of this invention are useful in methods of transporting the bioactive moiety across a polar epithelial membrane. Thus, this invention provides methods for parenteral administration of proteins without injection.
REFERENCES:
patent: 5696077 (1997-12-01), Johnson et al.
patent: 2002/0106370 (2002-08-01), Cardy
patent: 2004/0071731 (2004-04-01), Fitzgerald
patent: 2005/0079171 (2005-04-01), Fitzgerald et al.
patent: WO 86/06635 (1986-11-01), None
patent: WO 95/07297 (1995-03-01), None
patent: WO 98/20135 (1998-05-01), None
patent: WO 9820135 (1998-05-01), None
patent: WO 98/42876 (1998-10-01), None
patent: WO 98/42876 (1998-10-01), None
patent: WO 00/46246 (2000-08-01), None
patent: WO 01/30392 (2001-05-01), None
patent: WO 01/31020 (2001-05-01), None
Mrsny et al (Vaccine 17 Mar. 1999, p. 1425-1433).
Fitzgerald et al (The Journal of Biological Chemistry, vol. 272, No. 16, Apr. 17, 1998, p. 9951-9958).
Andreasen, P.A. et al., “Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes.”FEBS Letters, vol. 338, No. 3; pp. 239-245 (1994).
Cavallaro, U. et al., “Targeting plant toxins to the urokinase and α-2-macroglobulin receptors.”Semin. Cancer Biol., vol. 6, No. 5; pp. 269-278 (1995).
Daugherty, A.L. et al., “Epithelial application ofPseudomonas aeruginosaexotoxin A results in a selective targeting to cells in the liver, spleen and lymph node.”J. Controlled Release, vol. 65, Nos. 1-2; pp. 297-302 (2000).
Fitzgerald, D.J., et al., “Characterization of V3 loop-Pseudonomasexotoxin chimeras. Candidate vaccines for human immunodeficiency virus-1.”J. Biol. Chem., vol. 273, No. 16; pp. 9951-9958 (1998).
Herz J. and D.K Strickland, “LRP: a multifunctional scavenger and signaling receptor.”J Clin Invest., vol. 108, No. 6; pp. 779-784. (2001).
Maziere, J.C. et al., “Processing and characterization of the low density lipoprotein receptor in the human colonic carcinoma cell subclone HT29-18: a potential pathway for delivering therapeutic drugs and genes.”Biosci. Rep., vol. 12, No. 6; pp. 483-494 (1992).
Melman, L. et al., “High affinity binding of receptor-associated protein to heparin and low density lipoprotein receptor-related protein requires similar basic amino acid sequence motifs.”J. Biol. Chem., vol. 276, No. 31; pp. 29338-29346 (2001).
Mrsny R.J. et al.. “Mucosal administration of a chimera composed ofPseudomonasexotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses.”Vaccine, vol. 17, Nos. 11-12; pp. 1425-1433 (1999).
Versluis, A.J. et al., “Stable incorporation of a lipophilic daunorubicin prodrug into apoliproteln E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo.”J. Pharmacol. Experiment Therap., vol. 289, No. 1; pp. 1-7 (1999).
Zdanovsky, A.G. et al., “TargetingPseudomonasand diphtheria toxins to the alpha-2-macroglobulin receptor via RAP-toxin and PAI-I-toxin fusions.”Prot. Engin., vol. 8, No. Suppl., pp. 123 (1995).
U.S. Appl. No. 09/462,682, filed Apr. 28, 2000, Fitzgerald.
Daugherty Ann
FitzGerald David J.
McKee Marian
Mrsny Randall J.
Ford Vanessa L.
Genentech Inc.
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Delivery of proteins across polar epithelial cell layers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delivery of proteins across polar epithelial cell layers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery of proteins across polar epithelial cell layers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4188799